Low-density lipoprotein cholesterol (LDLC), also known as ‘bad cholesterol,’ contributes to plaque buildup in the arteries and causes damage, making it a ‘silent killer’ ...
The cholesterol-lowering drug has been classed as a breakthrough therapy for homozygous familial hypercholesterolaemia (HoFH) by the FDA, which is due to deliver a decision on the marketing ...
Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment.
Aug. 14, 2024 — More than a quarter of Australians over the age of 50 take cholesterol-lowering drugs to prevent heart disease and strokes, but our bodies also need cholesterol to survive.
Strokes remain among the leading causes of death and disability worldwide, often developing from underlying health conditions that frequently go undet ...